STOCK TITAN
  1. Home
  2. News
  3. CDNA

CareDx to to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

CareDx’s management is also scheduled to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021 at 3:30 PM EST. Interested parties can access the live and archived webcast at investors.caredxinc.com.

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

Investor Relations
Greg Chodaczek
347-620-7010
investor@caredx.com 


Stock CDNA logo
Caredx Inc

NASDAQ:CDNA

CDNA Rankings

#3164 Ranked by Market Cap
#5231 Ranked by Stock Gains
N/A Ranked by Dividends

CDNA Latest News

Apr 19, 2024
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Apr 16, 2024
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
Apr 9, 2024
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
Mar 11, 2024
CareDx Appoints Bryan Riggsbee to Its Board of Directors
Feb 28, 2024
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results

CDNA Stock Data

Medical Laboratories
Health Care and Social Assistance
Link
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
US
South San Francisco

About CDNA

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos